NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis $1.19 -0.07 (-5.56%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$1.18 0.00 (-0.42%) As of 03/10/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Zura Bio Stock (NASDAQ:ZURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zura Bio alerts:Sign Up Key Stats Today's Range$1.15▼$1.3050-Day Range$1.15▼$2.5852-Week Range$1.10▼$6.35Volume166,467 shsAverage Volume391,561 shsMarket Capitalization$77.70 millionP/E RatioN/ADividend YieldN/APrice Target$15.80Consensus RatingBuy Company OverviewZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Read More… Remove Ads Zura Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreZURA MarketRank™: Zura Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 667th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZura Bio has only been the subject of 2 research reports in the past 90 days.Read more about Zura Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zura Bio are expected to decrease in the coming year, from ($0.65) to ($0.78) per share.Price to Book Value per Share RatioZura Bio has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Zura Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.59% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Zura Bio has recently increased by 5.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.59% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Zura Bio has recently increased by 5.12%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment0.59 News SentimentZura Bio has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zura Bio this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zura Bio's insider trading history. Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ZURA Stock News HeadlinesZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.March 11, 2025 | Crypto Swap Profits (Ad)We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business GrowthJanuary 22, 2025 | finance.yahoo.comZura Bio Highlights Strategic Goals and Clinical AdvancesJanuary 13, 2025 | tipranks.comZura Bio initiates Phase II systemic sclerosis treatment trialDecember 25, 2024 | msn.comZura Bio to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | businesswire.comZura Bio submits protocol to FDA for Phase 2 study of TibulizumabNovember 15, 2024 | markets.businessinsider.comSee More Headlines ZURA Stock Analysis - Frequently Asked Questions How have ZURA shares performed this year? Zura Bio's stock was trading at $2.50 at the start of the year. Since then, ZURA stock has decreased by 52.4% and is now trading at $1.19. View the best growth stocks for 2025 here. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.12. Who are Zura Bio's major shareholders? Zura Bio's top institutional shareholders include JPMorgan Chase & Co. (4.03%), ADAR1 Capital Management LLC (3.18%), Geode Capital Management LLC (1.46%) and Millennium Management LLC (1.07%). Insiders that own company stock include Someit Sidhu, Van Amstel Arnout Ploos, Michael Howell, Kiran Nistala and Parvinder Thiara. View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zura Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS). Company Calendar Last Earnings11/07/2024Today3/10/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZURA CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$15.80 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,227.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.36% Return on Assets-29.81% Debt Debt-to-Equity RatioN/A Current Ratio10.36 Quick Ratio10.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book0.64Miscellaneous Outstanding Shares65,294,000Free Float50,864,000Market Cap$77.70 million OptionableOptionable Beta0.06 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ZURA) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.